Prognostic value of radiologic and pathological response in colorectal cancer liver metastases upon systemic induction treatment: subgroup analysis of the CAIRO5 trial

RECIST may not be optimal for assessing treatment response with current systemic regimens. We evaluated RECIST, morphologic, and pathologically documented response (pathological response) in patients with initially unresectable colorectal cancer liver-only metastases (CRLM). Four hundred and eighty-...

Full description

Saved in:
Bibliographic Details
Published in:ESMO open 2024-12, Vol.9 (12), p.104075, Article 104075
Main Authors: Bond, M.J.G., Mijnals, C., Bolhuis, K., van Amerongen, M.J., Engelbrecht, M.R.W., Hermans, J.J., van Lienden, K.P., May, A.M., Swijnenburg, R.-J., Punt, C.J.A.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - pharmacology
Bevacizumab - therapeutic use
Camptothecin - analogs & derivatives
Camptothecin - pharmacology
Camptothecin - therapeutic use
colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Female
Fluorouracil - pharmacology
Fluorouracil - therapeutic use
Humans
Induction Chemotherapy - methods
Leucovorin - pharmacology
Leucovorin - therapeutic use
liver metastases
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Male
Middle Aged
morphologic response
Organoplatinum Compounds - pharmacology
Organoplatinum Compounds - therapeutic use
Panitumumab - pharmacology
Panitumumab - therapeutic use
pathological response
Prognosis
RECIST
Response Evaluation Criteria in Solid Tumors
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RECIST may not be optimal for assessing treatment response with current systemic regimens. We evaluated RECIST, morphologic, and pathologically documented response (pathological response) in patients with initially unresectable colorectal cancer liver-only metastases (CRLM). Four hundred and eighty-nine patients from the phase III CAIRO5 trial were included who were treated with FOLFOX/FOLFIRI/FOLFOXIRI and bevacizumab or panitumumab. The association of the different response tools with overall survival (OS) was evaluated for all patients, and with early recurrence (
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2024.104075